Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma von Shiah, H.‐S., Chen, C.‐Y., Dai, C.‐Y., Hsiao, C.‐F., Lin, Y.‐J., Su, W.‐C., Chang, J.‐Y., Whang‐Peng, J., Lin, P.‐W., Huang, J.‐D., Chen, L.‐T.

Volltext

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients von Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., Wang, Y. W., Yeh, C. G., Chiang, N. J., Chang, J. Y., Chen, L. T.

Volltext

Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients von Dai, M.-S., Chao, T.-Y., Chao, T.-C., Chiu, C.-F., Lu, Y.-S., Shiah, H.-S., Wu, Y.-Y., Gerald Fetterly, G., Hung, N., Cutler, D.L., Kwan, R., Douglas Kramer, D., Chan, W.-K., Hung, T.

Volltext

Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23 von SHIAH, H.-S, KUO, Y.-Y, LIN, K.-H, TIEN, H.-F, TANG, J.-L, HUANG, S.-Y, YAO, M, TSAY, W, CHEN, Y.-C, WANG, C.-H, SHEN, M.-C, LIN, D.-T

Volltext

α‐fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma von CHEN, L.‐T., LIU, T.‐W., CHAO, Y., SHIAH, H.‐S., CHANG, J.‐Y., JUANG, S.‐H., CHEN, S.‐C., CHUANG, T.‐R., CHIN, Y.‐H., WHANG‐PENG, J.

Volltext

Effective sirolimus treatment for refractory spindle cell haemangioma von Ho, C.B., Hsieh, K., Chen, W.Y., Lin, Y.T., Chiou, J.F., Lee, H.L., Shiah, H.S.

Volltext

Pulmonary embolism after transcatheter arterial chemoembolization von SHIAH, H.-S., LIU, T.-W., CHEN, L.-T., CHANG, J.-Y., LIU, J. M., CHUANG, T.-R., LEE, W.-S., WHANG-PENG, J.

Volltext

71MO OBI-833 was safe and immunogenic, without treatment-related SAEs, in a phase I dose-escalation trial von Shiah, H-S., Strauss, J.F., Lin, C-C., Ou, C-C., Yen, Y.

Volltext

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer von Chen, J.S., Hsu, C., Chiang, N.J., Tsai, C.S., Tsou, H.H., Huang, S.F., Bai, L.Y., Chang, I.C., Shiah, H.S., Ho, C.L., Yen, C.J., Lee, K.D., Chiu, C.F., Rau, K.M., Yu, M.S., Yang, Y., Hsieh, R.K., Chang, J.Y., Shan, Y.S., Chao, Y., Chen, L.T., Shen, Wen-Chi, Hsu, Hung-Chih, Hsu, Chih-Hung, Shen, Ying-Chun, Wang, Tsang-En, Li, Chung-Pin, Chen, Ming-Huang, Kao, Wei-Yao, Chang, Ping-Ying, Wu, Cheng-Chung, Teng, Chien-Lin, Lu, Chang-Hsien, Lin, Shyh-Jer, Wang, Being-Whey, Chen, Yen-Yang, Chin, Yung-Hsin, Chung, Tsai-Rong, Yu, Wei-Lan, Lee, Mei-Hua, Lin, Ling-Fang, Lin, Pei-Chyi, Wu, Ya-Ling, Wang, Hui-Ling, Lu, Li-Ju, Chen, Shiang-Yi, Wu, Chih-Chu, Wei, Te-Chih

Volltext

1533P Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carci... von Sun, M., Spigel, D.R., Lee, Y-J., Yoon, H., Liu, Y., Ahern, E., Harris, S., Lee, G-W., Yan, D., Chen, J., Shiah, H-S., Deng, T., Zheng, H., Tan, W., Zhou, Z., Wang, R., Ba, Y.

Volltext

1017P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamo... von Yu, Y., Huang, D., Gao, B., Zhao, J., Hu, Y., Zhuang, W., Kao, S., Xu, W., Yao, Y., Yang, T-Y., Lee, Y., Kim, J-S., Shiah, H-S., Wang, R., Zheng, H., Tan, W., Gao, R., Kim, H.R., Lu, S.

Volltext

397P A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients von Ho, C-L., Lee, K-Y., Shiah, H-S., Lin, C-C., Ou, C-C., Tsai, C-E., Yang, P-C.

Volltext

1208P Final results of APOLLO study: Overall survival (OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer... von Lu, S., Wang, Q., Zhang, G., Dong, X., Yang, C-T., Song, Y., Chang, G-C., Lu, Y., Pan, H., Chiu, C-H., Wang, Z., Feng, J., Zhou, J., Xu, X., Guo, R., Chen, J., Yang, H., Chen, Y., Yu, Z., Shiah, H-S.

Volltext

Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma von Italiano, A., Cassier, P., Roda, D., Lin, C.-C., Peltola, K., Gazzah, A., Shiah, H.-S., Calvo, E., Tosi, D., Gao, B., warburton, L., Tanner, M., Englert, S., Lambert, S., Parikh, A., Afar, D., Vosganian, G., Moreno, V.

Volltext

1288P - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma von Italiano, A., Cassier, P., Roda, D., Lin, C.-C., Peltola, K., Gazzah, A., Shiah, H.-S., Calvo, E., Tosi, D., Gao, B., warburton, L., Tanner, M., Englert, S., Lambert, S., Parikh, A., Afar, D., Vosganian, G., Moreno, V.

Volltext

1288PSafety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma von Italiano, A, Cassier, P, Roda, D, Lin, C-C, Peltola, K, Gazzah, A, Shiah, H-S, Calvo, E, Tosi, D, Gao, B, warburton, L, Tanner, M, Englert, S, Lambert, S, Parikh, A, Afar, D, Vosganian, G, Moreno, V

Volltext

287PDOral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients von Dai, M-S, Chao, T-Y, Chao, T-C, Chiu, C-F, Lu, Y-S, Shiah, H-S, Wu, Y-Y, Gerald Fetterly, G, Hung, N, Cutler, D L, Kwan, R, Douglas Kramer, D, Chan, W-K, Hung, T

Volltext

Modulatory effect of crocetin on aflatoxin B1 cytotoxicity and DNA adduct formation in C3H10T1/2 fibroblast cell von WANG, C.-J, SHIAH, H.-S, LIN, J.-K

Volltext

126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lun... von Frentzas, S., Meniawy, T., Kao, S.C-H., Coward, J., Clay, T.D., Singhal, N., Black, A., Xu, W., Kumar, R., Lee, Y., Lee, G-W., Liao, W., Zhong, D., Shiah, H-S., Chen, Y-M., Gao, R., Wang, R., Zheng, H., Tan, W., Cho, E.K.

Volltext

Pseudomonas exotoxin A-epidermal growth factor (EGF) mutant chimeric protein as an indicator for identifying amino acid residues important in EGF-receptor interaction von Shiah, H S, Chen, T Y, Chang, C M, Chow, J T, Kung, H J, Hwang, J

Volltext